[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350287-105":3,"doc-detail-350287-en":81,"detail-sidebar-cat-0-en-105":115},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prmt3-in-cancer-arginine-methylation-as-a-driver-of-tumor-metabolism-immune-evasion-and-therapeutic-resistance","PRMT3 in cancer: arginine methylation as a driver of tumor metabolism, immune evasion, and therapeutic resistance","","PRMT3 is a type I arginine methyltransferase that catalyzes asymmetric dimethylation of arginine residues on multiple substrate proteins. Dysregulation of PRMT3 is reported across diverse malignancies, where arginine methylation links PRMT3 to signaling programs controlling tumor progression, metabolic adaptation, immune modulation, and therapy resistance. Mechanistic evidence highlights effects on RNA-associated networks, metabolic reprogramming, PD-L1 and innate immune signaling, and mechanisms supporting oncogenic transcript stability and drug resistance. This review summarizes PRMT3 structure, catalysis, and cancer functions.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prmt3-in-cancer-arginine-methylation-as-a-driver-of-tumor-metabolism-immune-evasion-and-therapeutic-resistance/350287/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prmt3-in-cancer-arginine-methylation-as-a-driver-of-tumor-metabolism-immune-evasion-and-therapeutic-resistance/350287.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biological activity does PRMT3 perform?","Question",{"text":63,"@type":64},"PRMT3 is a type I arginine methyltransferase that catalyzes asymmetric dimethylation of arginine residues on diverse substrate proteins.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is PRMT3 linked to tumor metabolism and progression?",{"text":68,"@type":64},"Through arginine methylation of regulatory proteins, PRMT3 is associated with metabolic adaptation and signaling pathways supporting tumor growth and progression.",{"name":70,"@type":61,"acceptedAnswer":71},"In what ways can PRMT3 contribute to immune evasion and therapy resistance?",{"text":72,"@type":64},"PRMT3 has been reported to influence immune evasion, including effects on PD-L1 and innate immune signaling such as cGAS–STING, and to promote therapeutic resistance via transcript stabilization, immunometabolic remodeling, and drug efflux regulation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350287,1790190694,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":86,"file_id":87,"file_url":88,"file_type":89,"file_size":90,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":91,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97,"preview_page_count":33,"preview_urls":98},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 01 May 2026  \nDOI 10.3389/fimmu.2026.1828765  \nOPEN ACCESS  \nEDITED BY  \nShaoquan Zheng,  \nSun Yat-sen University, China  \nREVIEWED BY  \nLiang-min Fu,  \nCentral South University, China Xuegang Niu,  \nThe First Afﬁliated Hospital of Fujian Medical University, China  \n*CORRESPONDENCE  \nXin Pan  \n [panxi081001@163.com](panxi081001@163.com)  \nRECEIVED 12 March 2026  \nREVISED 11 April 2026  \nACCEPTED 14 April 2026  \nPUBLISHED 01 May 2026  \nCITATION  \nJin H, Huang H and Pan X (2026) PRMT3 in cancer: arginine methylation as adriver of tumor metabolism, immune evasion, and therapeutic resistance. Front. Immunol. 17:1828765 .  \ndoi: 10.3389/fimmu.2026.1828765  \nCOPYRIGHT  \n© 2026 Jin, Huang and Pan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPRMT3 in cancer: arginine methylation as a driver of tumor metabolism, immune evasion, and therapeutic resistance  \nHui Jin 1, Hua Huang 2 and Xin Pan 3*  \n1 Department of Respiratory Medicine, Afﬁliated People ’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, China, 2 Department of Oncology, Zhenjiang Fourth People’s Hospital, Zhenjiang, Jiangsu, China, 3Zhenjiang 359 Hospital, Zhenjiang, Jiangsu, China  \nProtein arginine methyltransferase 3 (PRMT3) is a type I arginine methyltransferase that catalyzes asymmetric dimethylation of arginine residues on diverse substrate proteins. Initially characterized as a regulator of ribosomal protein methylation, PRMT3 has more recently been implicated in several cancer-related processes. Accumulating evidence suggests that PRMT3 is dysregulated in a variety of malignancies, including hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer. Through arginine methylation of selected regulatory proteins, PRMT3 has been linked to signaling pathways associated with tumor progression, metabolic adaptation, immune modulation, and therapeutic resistance. Mechanistically, available studies indicate that PRMT3 can regulate RNA-associated networks by methylating RNAbinding proteins and epitranscriptomic regulators such as IGF2BP1 and METTL14, thereby inﬂuencing mRNA stability and gene expression programs. In addition, PRMT3 has been reported to contribute to tumor metabolic reprogramming by promoting glycolytic activity and modulating amino acid metabolism through factors including HIF1A, PDHK1, and IDO1 . These alterations may support tumor growth and, in some contexts, inﬂuence the tumor immune microenvironment. PRMT3 has also been associated with immune evasion, for example through effects on PD-L1 expression and innate immune signaling pathways such as cGAS–STING. Moreover, emerging evidence links PRMT3 to therapeutic resistance through mechanisms involving oncogenic transcript stabilization, immunometabolic remodeling, and drug efﬂux regulation. In this review, we summarize the current understanding of PRMT3 structure, catalytic mechanisms, and biological functions in cancer. We further discuss its emerging roles in metabolic regulation, immune suppression, and therapy resistance, while distinguishing mechanisms directly supported within speciﬁc cancer contexts from broader conceptual models inferred across studies. Overall, current evidence supports PRMT3 as an emerging and context-dependent regulator of tumor biology and a potential target for anticancer therapy.  \nKEYWORDS  \narginine methylation, immune evasion, PRMT3, therapeutic resistance, tumor metabolism  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nHighlights  \n• PRMT3-mediated arginine methy","cbCaiuFVhbKm6iS5","https://ap.wps.com/l/cbCaiuFVhbKm6iS5","pdf",2507448,21,"English","# Highlights\n# 1 Introduction","[{\"question\":\"What biological activity does PRMT3 perform?\",\"answer\":\"PRMT3 is a type I arginine methyltransferase that catalyzes asymmetric dimethylation of arginine residues on diverse substrate proteins.\"},{\"question\":\"How is PRMT3 linked to tumor metabolism and progression?\",\"answer\":\"Through arginine methylation of regulatory proteins, PRMT3 is associated with metabolic adaptation and signaling pathways supporting tumor growth and progression.\"},{\"question\":\"In what ways can PRMT3 contribute to immune evasion and therapy resistance?\",\"answer\":\"PRMT3 has been reported to influence immune evasion, including effects on PD-L1 and innate immune signaling such as cGAS–STING, and to promote therapeutic resistance via transcript stabilization, immunometabolic remodeling, and drug efflux regulation.\"}]","PRMT3 in cancer: arginine methylation as a driver of tumor metabolism, immune evasion, and therapeutic resistance | PDF",1790088235,53,[99,103,107,111],{"page_no":22,"url":100,"width":101,"height":102},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1addafa3ceb5ed818dfccf3d99682412.webp",983,1389,{"page_no":26,"url":104,"width":105,"height":106},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60a734c8d0a04fe9cc79cfe567cade38.webp",982,1388,{"page_no":30,"url":108,"width":109,"height":110},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c8dd3d1f516b953ac2391263e5d8aa4.webp",981,1386,{"page_no":33,"url":112,"width":113,"height":114},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f23896d0e3b4ef5f5f9a0778f65282b5.webp",980,1385,{"code":4,"msg":82,"data":116},[117,121,125,129,134,139,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":118,"show_sort_weight":119,"slug":120},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":122,"show_sort_weight":123,"slug":124},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":126,"show_sort_weight":127,"slug":128},"Exam",70,"exam",{"id":130,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},5,"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":130,"slug":162},19,"General","general"]